Cargando…

The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis

PURPOSE OF REVIEW: Biologics are well established in the treatment of many immuno-inflammatory diseases including inflammatory bowel disease (IBD). However, although primary sclerosing cholangitis (PSC) is closely associated with IBD, the role of biologics in PSC remains uncertain. Many new biologic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lynch, Kate D., Keshav, Satish, Chapman, Roger W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445403/ https://www.ncbi.nlm.nih.gov/pubmed/31008013 http://dx.doi.org/10.1007/s11901-019-00456-2

Ejemplares similares

Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?
por: Chapman, Roger W, et al.
Publicado: (2017)

Why Doesn’t Primary Biliary Cholangitis Respond to Immunosuppressive Medications?
por: Molinaro, Antonio, et al.
Publicado: (2017)

Serum Immunoglobulin G4 and Immunoglobulin G1 for Distinguishing Immunoglobulin G4-Associated Cholangitis From Primary Sclerosing Cholangitis
por: Boonstra, Kirsten, et al.
Publicado: (2014)

Immunoglobulin G4(+) B‐cell receptor clones distinguish immunoglobulin G 4‐related disease from primary sclerosing cholangitis and biliary/pancreatic malignancies
por: Doorenspleet, Marieke E., et al.
Publicado: (2016)

Electrostatic Modifications of the Human Leukocyte Antigen-DR P9 Peptide-Binding Pocket and Susceptibility to Primary Sclerosing Cholangitis
por: Hov, Johannes R, et al.
Publicado: (2011)

Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice
por: Zhou, Mei, et al.
Publicado: (2016)

Pregnane-X-Receptor Controls Hepatic Glucuronidation During Pregnancy and Neonatal Development in Humanized UGT1 Mice
por: Chen, Shujuan, et al.
Publicado: (2012)

Intrahepatic Cholestasis of Pregnancy Levels of Sulfated Progesterone Metabolites Inhibit Farnesoid X Receptor Resulting in a Cholestatic Phenotype
por: Abu-Hayyeh, Shadi, et al.
Publicado: (2013)

Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+)-taurocholate cotransporting polypeptide knockout mice
por: Slijepcevic, Davor, et al.
Publicado: (2015)

Vitamin D Nuclear Receptor Deficiency Promotes Cholestatic Liver Injury by Disruption of Biliary Epithelial Cell Junctions in Mice
por: Firrincieli, Delphine, et al.
Publicado: (2013)

Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum
por: Abu‐Hayyeh, Shadi, et al.
Publicado: (2015)

Conjugated Bilirubin Triggers Anemia by Inducing Erythrocyte Death
por: Lang, Elisabeth, et al.
Publicado: (2015)

Association of Severe Intrahepatic Cholestasis of Pregnancy With Adverse Pregnancy Outcomes: A Prospective Population-Based Case-Control Study
por: Geenes, Victoria, et al.
Publicado: (2014)

Human intrahepatic regulatory T cells are functional, require IL‐2 from effector cells for survival, and are susceptible to Fas ligand‐mediated apoptosis
por: Chen, Yung‐Yi, et al.
Publicado: (2016)

The toxin biliatresone causes mouse extrahepatic cholangiocyte damage and fibrosis through decreased glutathione and SOX17
por: Waisbourd‐Zinman, Orith, et al.
Publicado: (2016)

Soluble Adenylyl Cyclase Regulates Bile Salt‐Induced Apoptosis in Human Cholangiocytes
por: Chang, Jung‐Chin, et al.
Publicado: (2016)

Cholestasis‐induced adaptive remodeling of interlobular bile ducts
por: Vartak, Nachiket, et al.
Publicado: (2016)

The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia
por: Mohanty, Sujit K., et al.
Publicado: (2017)

Defects in myosin VB are associated with a spectrum of previously undiagnosed low γ‐glutamyltransferase cholestasis
por: Qiu, Yi‐Ling, et al.
Publicado: (2017)

Secondary sclerosing cholangitis: mimics of primary sclerosing cholangitis
por: Ludwig, Daniel R., et al.
Publicado: (2022)

A novel serum metabolomic panel distinguishes IgG4‐related sclerosing cholangitis from primary sclerosing cholangitis
por: Radford‐Smith, Daniel E., et al.
Publicado: (2022)

Bile acids increase steroidogenesis in cholemic mice and induce cortisol secretion in adrenocortical H295R cells via S1PR2, ERK and SF‐1
por: Liu, Lei, et al.
Publicado: (2019)

Fatigue in primary sclerosing cholangitis is associated with sympathetic over‐activity and increased cardiac output
por: Dyson, Jessica K., et al.
Publicado: (2014)

Unique patterns of glycosylation in immunoglobulin subclass G4‐related disease and primary sclerosing cholangitis
por: Culver, Emma L, et al.
Publicado: (2018)

Impact on follow‐up strategies in patients with primary sclerosing cholangitis
por: Bergquist, Annika, et al.
Publicado: (2022)

Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
por: Lynch, Kate D., et al.
Publicado: (2020)

A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose
por: Nakajima-Kato, Yuko, et al.
Publicado: (2022)

A novel selective spleen tyrosine kinase inhibitor SKI-O-703 (cevidoplenib) ameliorates lupus nephritis and serum-induced arthritis in murine models
por: Cho, Somi, et al.
Publicado: (2022)

Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response
por: Valli, Atte, et al.
Publicado: (2022)

The longitudinal loss of islet autoantibody responses from diagnosis of type 1 diabetes occurs progressively over follow-up and is determined by low autoantibody titres, early-onset, and genetic variants
por: Williams, C L, et al.
Publicado: (2022)

Combination therapy of a TRPV2 agonist with a TNF inhibitor achieves sustained suppression of disease severity and reduced joint damage
por: Laragione, Teresina, et al.
Publicado: (2022)

CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients
por: Vandewalle, Julie, et al.
Publicado: (2023)

Diagnostic markers and potential therapeutic agents for Sjögren’s syndrome screened through multiple machine learning and molecular docking
por: Zhou, Liqing, et al.
Publicado: (2023)

Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study
por: Gu, Tao, et al.
Publicado: (2015)

Complement C4 Copy Number Variation is Linked to SSA/Ro and SSB/La Autoantibodies in Systemic Inflammatory Autoimmune Diseases
por: Lundtoft, Christian, et al.
Publicado: (2022)

The Cost-effectiveness of Celecoxib versus Non-steroidal Anti-inflammatory Drugs plus Proton-pump Inhibitors for Treating Osteoarthritis in Algeria
por: Hammoumraoui, Nadir, et al.
Publicado: (2013)

Polygenic risk score predicts risk of primary sclerosing cholangitis in inflammatory bowel disease
por: Wang, Ming-Hsi, et al.
Publicado: (2023)

A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases
por: Kastrati, Kastriot, et al.
Publicado: (2022)

The Simple Cholestatic Complaints Score is a valid and quick patient‐reported outcome measure in primary sclerosing cholangitis
por: van Munster, Kim N., et al.
Publicado: (2020)

Development of a Conceptual Model to Understand Disease Burden in Patients With Systemic Lupus Erythematosus and Organ Damage
por: Broderick, Lynne, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i26qo3mjl95rm1kov0b1pkt9nm